Background We wished to determine the range of treated systolic (SBP) and diastolic blood pressure (DBP) associated with the best survival in hypertensive patients.
Methods and Results
We conducted a cohort study of patients enrolled in the DoH Hypertension Care Computer Project. Five specialist hypertension clinics (95% of patients) and general practitioners (5%) followed 6214 patients (3070 men and 3144 women) with an average age of 52 years for a mean of 107 months. Total, cardiovascular, ischemic heart disease, (IHD) and stroke mortality were the outcome measures. Age-adjusted relative hazard rates were calculated giving the effect on mortality of systolic or diastolic pressure being higher by 1 mm Hg. In men the optimal level of SBP for all four measures of mortality was the lowest pressure range observed, 92 to 133 mm Hg (median 127). For women the treated SBP range of 96 to 148 mm Hg (median 137) was associated with a low total mortality and also with low to moderate rates for IHD and stroke mortality. Relative hazard rates (P<.001) for IHD mortality were 1.010 for men and 1.013 for women and for stroke mortality were 1.018 and 1.021, respectively. The results were similar in men under and over the age of 60. SBP and DBP tended to be more important in he blood pressure (BP) achieved during treat-T ment is an important predictor of survival and is more important than the untreated level of pressure.' Falls in BP may not be solely the result of antihypertensive drugs but also may be influenced by other factors such as weight loss, reduction in alcohol intake, and reduction in sodium intake. The situation is younger than older women. For treated DBP in men, a pressure of 55 to 94 mm Hg (median 87) was associated with a low total mortality. The lowest stroke mortality in men was observed for a DBP range of 55 to 83 mm Hg (median 80) but with a tendency for an increase in IHD mortality. For women DBP <95 mm Hg (range 55 to 94, median 87) also was associated with a low total mortality. IHD mortality in women was not closely related to treated DBP, relative hazard rate=1.003, [95% confidence index (CI); 0.990,1.017] but the relative hazard rate for men was 1.011, (95% CI; 1.000,1.022). The relative hazard rates for treated DBP and stroke were high at 1.035 and 1.028 for men and women, respectively (P<.001). IHD mortality increased in the one third of patients with the greatest fall in DBP on treatment, provided they were not initially in the one-third group with highest untreated DBP.
Conclusions 'The best overall survival was associated with a treated SBP of <134 mm Hg in men and <149 mm Hg in women and a treated DBP of <95 mm Hg. (Circulation. 1994;90:225-233.) Key Words * blood pressure * hypertension * ischemia complex as some of these factors, for example, weight loss, may be the result of deliberate actions by the patient and associated with a good survival or, alternatively, reflect serious illness with a poor outcome. Moreover, myocardial disease may lower BP and itself be associated with a poor survival. Nevertheless, it is important to try to identify the "safest" range of treated BP. There have been many reports2-10 of the optimal BP to be achieved in the prevention of death from ischemic heart disease (IHD). The present report expands these observations to consider total mortality, cardiovascular mortality, and death from IHD and stroke in relation to treated diastolic (DBP) and systolic blood pressure (SBP).
Methods
The DoH Hypertension Care Computer Project is a multicenter computer-based observational study started in 1971 of patients being treated for hypertension in the United Kingdom and currently contains records of some 11 663 patients recruited up to December 31, 1987. Patients entered the system on presentation to one of the hospital hypertension clinics or general practices involved in the study. Details of presentation and subsequent attendances are recorded. The Office of Population Censuses and Surveys holds a flagged record of all these patients and gives notification of any emigration or deaths.
The results presented in this report refer to the data base of 6214 patients who had received antihypertensive medication for a minimum of 1 year to give measurements of treated BP averaged from 3 to 12 months from presentation and had been followed for ascertainment of vital status up to March 31, 1990. All patients referred to the hypertension clinics or identified by the general practitioners were included irrespective of BP. The readings over the first 3 months were excluded as this was the interval during which treatment was usually stabilized. The present analytical data base was created on December 31, 1986; therefore, 1477 patients presenting after that date were excluded. Of the remaining 10 186 patients, 129 were excluded as they died within the first year, and 3832 (38%) did not have a measurement of BP between 3 and 12 months of referral. Sex was unknown in 6 patients and age at presentation was missing in 5 patients. The great majority of the patients (95%) were attending a clinic at one of the following hospitals: King's College Hospital, London; Hammersmith Hospital, London; John Radcliffe Hospital, Oxford; Dudley Road Hospital, Birmingham; and Aberdeen Royal Infirmary. General practitioners in Kentish Town (London), Harlow, Oxford, and Norwich saw the remaining 5%.
Survival has been determined for a maximum of 228 months (average, 107 months). The causes of death and risk factors for survival have previously been published" as has the relationship between BP control and mortality when 2145 patients had been followed for an average of 48 months.5 Details of the relationship between BP control and IHD12 and stroke13 have been reported separately.
The treated BP was the average of pressures (one per visit) for patients given treatment during the period 3 to 12 months after presentation (a mean of two visits). Two measurements in different bodily positions were made at each visit, but only one measure was selected. Supine BPs were chosen for analysis, but in the event of these being unavailable, sitting BPs were used instead. BP was measured by experienced observers but without formal standardization. Most observers used phase V Korotkoff. The treatment period of 3 to 12 months was chosen, because by this time BP had fallen an average of 29/18 mm Hg (systolic/diastolic) from the untreated level and fell only a further 3/2 mm Hg between this period and the average of the second year of follow-up. Moreover, 84% of first-year average SBPs were within±20 mm Hg of the secondyear estimate and, similarly, 87% of average DBPs were within ± 12.5 mm Hg. It is important to predict mortality with a measure of BP remote from and unbiased by the events leading to death.
The untreated pressure was either the first untreated reading within the first 3 months from presentation, or (if no such reading was available) the untreated pressure closest to and within 1 year before presentation. Untreated BPs were not available in 3884 of the 10 186 patients.
There were 1111 deaths. Death certificates were coded according to the eighth revision of the International Classification of Diseases for any mention of a cause of death. The codes for cardiovascular disease were 3900 to 4589 and 7950 to 7959, IHD 4100 to 4149, and stroke 4300 to 4389. Survival was assessed prospectively after the first year of treatment. The Cox proportional hazards model2 was used to test the strength of the association between mortality and treated BP after including age in the model. Either SBP or DBP was included, but not both. The two sexes were considered separately. Underlying cause and any mention mortality rates were calculated per 1000 patient years of observation by sex and by quintiles of BP strata and were age adjusted by the direct method. The percentage increases in mortality were calculated from the age-adjusted results. The results are presented graphically according to pressure ranges given on the figures. To examine differences in mortality between the BP levels, the Cox proportional hazards model included age and four dummy variables representing the second, third, fourth, and fifth levels of pressure. The relative hazard rate (RHR) gives the effect on mortality of increasing BP by 1 mm Hg when BP was treated as a continuous variable or the effect on mortality of being in a BP quintile compared with the lowest pressure quintile. For example an RHR of 1.01 for SBP indicates that an increase of 1 mm Hg in SBP would be associated with an increase in mortality rate of 1%. When the RHR for inclusion in a particular quintile of the BP distribution compared with the lowest quintile is discussed, it is termed relative risk (RR) to distinguish from the RHR for a continuous variable. Table 1 gives the characteristics of the men and women included in this analysis and the number of deaths. Fig 1 relates the death rate from all causes, any mention of cardiovascular diseases, any mention of IHD death, and any mention of stroke death according to quintiles of the treated (3 to 12 months) SBP in men.
Results
The RHR for treated SBP was 1.009 for total mortality and 1.012, 1.010, and 1.018 for cardiovascular, IHD, and stroke mortality, respectively. All RHRs were statistically significant at the P<.0001 level. A pressure <134 mm Hg (range 92 to 133, median 127) was associated with the lowest overall mortality.
The next lowest mortality was for the range 134 to 144 mm Hg (median 140). This was associated with a 28% increase in total mortality and 3%, 31%, and 44% increases in cardiovascular, IHD, and stroke mortality, respectively, compared with SBP <134 mm Hg. These increases in IHD and stroke mortality were not statistically significantly different from the range 92 to 133 mm Hg nor were the increases in mortality for the range 145 to 154 mm Hg ( Table 2) . IHD mortality was increased for ranges 155 to 169 mm Hg (RR 1.65, P=.03) and 170 to 290 mm Hg (RR 2.08, P=.001). The corresponding RRs for stroke mortality were similar at 1.55 (P=.3) and 2.86 (P=.01) ( Table 2 ).
In women ( Fig 2) the lowest total mortality was associated with an SBP < 149 mm Hg (range 96 to 148). The same range was associated with low IHD and stroke mortality. SBPs < 160 mm Hg appeared to be associated with a low risk of stroke death, but otherwise the range 149 to 159 mm Hg was associated with a 35%, 39%, and 109% increase in total, cardiovascular, and IHD mortality, respectively (100%=rate for 96 to 148 mm Hg). The RHRs for treated SBP were virtually the same in men and in women for total, cardiovascular, IHD, and stroke mortality ( (Table 2 ). The RHR for DBP and stroke mortality in women (1.028, P<.001) was similar to that in men. Table 3 compares the RHR and RRs (upper quintile of the distribution) in men and women under and over the age of 60. The results for those over 60 did not differ statistically from those under this age except for the RHR for SBP and IHD in women (RHR= 1.021 under age 60 and 1.011 over this age, P=.02).
In women over the age of 60 the RHRs (P=.05) and RRs for treated DBP and IHD mortality also tended to be lower than in younger women. This was also true for stroke mortality and SBP (P=.05) and DBP. There was no evidence of any difference between the age groups in men.
The relationship between tertiles of fall in BP with treatment in men and subsequent age-adjusted IHD It is also important to consider the levels of SBP in conjunction with the levels of DBP. Fig 6 gives the total mortality for men and women according to three levels of treated SBP in three strata of DBP. In men, the low total mortality is apparent for a treated SBP <140 mm Hg in the presence of a treated DBP of <95 mm Hg. In women it appears that attention should be paid to getting SBP < 160 mm Hg irrespective of DBP. relative hazard rates; IHD, ischemic
Discussion
In men an SBP below 134 mm Hg on treatment was associated with the lowest total, cardiovascular, IHD, and stroke mortality. We cannot say how far below this cutoff point the pressure should be lowered, but the median pressure was 127 mm Hg, and we can claim that this pressure level tended to have fewer deaths than SBPs on treatment of >134 mm Hg. Similarly, in women, low SBPs were to be preferred to higher levels, but low levels of total mortality were associated with a SBP <149 mm Hg. No extra benefit was observed at pressures <138 mm Hg, and a low stroke mortality was observed at all SBPs <160 mm Hg. In women there were few stroke deaths in the lower three quintiles of the treated SBP distribution and too much reliance cannot be placed on these results. Moreover, the importance of SBP in general, as assessed from the RHR, was as great in women as in men and these results support recommendations to aim for low levels of SBP made on the basis of other studies.14 The current findings are based on patients who mainly had moderate to severe hypertension with an average untreated BP of 184/111 mm Hg. Only 4% had mild hypertension (systolic <160 mm Hg and diastolic <95 mm Hg) and the good survival at lower treated pressures was not due to the inclusion of this small number of patients, as the results were essentially unchanged when they were excluded. 
-
There has been a great deal of discussion2-5 about the optimal level of DBP control since reports that mortality from myocardial infarction (MI) might increase in patients with treated DBPs <90 mm Hg (the J-shaped curve). In 1979 Stewart2 reported an RR of 5.4 for MI in hypertensive patients whose DBP fell below 90 mm Hg. In 1987 Cruickshank and colleagues3 showed a U-shaped curve for IHD events and treated DBP in 342 hypertensive men and women with a positive history of ischemia. The data were rather sparse, with only 10 MI deaths in the lower tertile of the distribution and 4 spondingly in the middle and upper tertiles, but the MI rate in the middle tertile was significantly lower than in the bottom and top tertiles. These articles were important because they provoked other authors to analyze their data and stimulated much discussion. Both the Glasgow Blood Pressure Clinic and a previous publication from our group found a J-shaped curve for IHD mortality and treated DBP.45 Both these studies were observational studies of patients attending hypertension clinics, similar to the study of Cruickshank et al,3 but the size of the data bases and the number of events were considerably larger. In the DoH Hypertension Care Computer Project, the increase in deaths occurred for treated DBPs <86 mm Hg, and in the Glasgow BP Clinics for DBPs <90 mm Hg. This was not found for women in the DoH Hypertension Care Computer Project, but the data were less reliable as they were based on fewer events. The Glasgow BP Clinic found a similar U-shaped curve for women. The MRC trial of mild to moderate hypertension7 showed no increase in risk for men with low average DBP during the trial (<90 mm Hg) but "there was some indication that this might be the case in women (P=.05)." However, the event rate was very low in women. There was no evidence for a J-shaped relation when a quadratic model was fitted or in patients with ECG evidence of ischemia at entry. However most patients with overt ischemia were excluded from the trial. Data from three other large randomized trials also showed a J curve for treated pressures and IHD events. One trial was in middle-aged men, the Heart Attack Primary Prevention in Hypertension study8; the other two studied elderly men and women: The European Working Party on Hypertension in the Elderly trial10 and the Hypertension in Elderly Patients in primary Care trial.9 These two trials in the elderly found that J curves also occurred in placebo or untreated patients and raised the possibility that J curves, at least in the elderly, were the consequence of disease rather than the cause.
The present analyses again show a tendency for IHD deaths to increase at DBPs in men <84 mm Hg with similar results in women for both IHD and stroke. With an RR of 1 at the lowest quintile of pressure, the RR for IHD and DBP 84 to 89 mm Hg in the present analysis was 0.83 in men and 0.86 in women. For DBP 90 to 94 mm Hg, the RR was 0.90 and 0.83 in men and women, respectively. The excess in the lowest pressure groups was not statistically significant and not due to inclusion of more current smokers, because only 30.9% and 19.5% of these men and women smoked versus 30.3% and 20.4%, respectively, for those with diastolic pressures 84 to 94 mm Hg.
In further analyses we have found that the J-shape phenomenon occurs mainly in patients >60 years.12 This agrees with the conclusions of many authors that the increased IHD mortality at low levels of treated DBP is due to patients with poor myocardial function entering the low pressure groups and subsequently dying of IHD.5s1'01516 The present analysis shows an increase in IHD mortality in both men and women when DBP fell by more than 25 mm Hg (men) or 23 mm Hg (women), provided that the patients did not have a very high untreated DBP to start with (more than 118 mm Hg in men or 114 mm Hg in women). It is not suggested that the patients were given too much antihypertensive medication. No such relation was observed for SBP, which falls similarly with treatment, and at no point was there an increased risk for IHD at lower levels of SBP. It is assumed that patients with higher falls had some degree of compromised myocardial function. When the initial DBP was very high and the fall in DBP resulted in more average levels, then no increase in mortality was observed. Moreover, the increase in mortality at low levels has been observed with placebo treatment10; thus, this phenomenon is unlikely to be a result of overtreatment with active antihypertensive drugs. The fall in BP observed in the present study is thought to be exaggerated by regression to the mean, a possible placebo effect, and maybe resolution of the "white coat" component of raised BP. Nevertheless, those patients with the greatest fall would be expected to have the highest reductions in a double-blind placebo controlled investigation including repeated and standardized measurements.
The alternative view has been put forward by Cruickshank.17 Hypertensive patients have left ventricular hypertrophy and an increased myocardial oxygen consumption. As coronary blood flow, in contrast to cerebral blood flow, depends mainly on DBP,18 then ischemia may develop. Farnett and her colleagues19 also argue that oxygen extraction may be near maximum before BP lowering, and autoregulation may then fail. They also suggest that lowering the coronary flow may increase blood viscosity and platelet adhesiveness and that areas of ischemic myocardium may cause a buildup of "metabolic gradients, giving rise to ventricular dysrhythmias." A trial is in progress20 that randomizes patients to different goal BPs, but in the absence of experimental evidence we must consider what we learn from the observational studies. It is generally agreed that concerns are limited to an excess of cardiac mortality with low DBP and that SBP and stroke mortality are less implicated in such a phenomenon. Farnett et a119 stated that we are "faced with the uncomfortable choice of whether to attempt to prevent cerebrovascular events at the expense of cardiac events or vice versa." The present analysis suggests that this concern is misplaced. The reduction in stroke events is a fact and an increase in IHD events is very much unproved.
For SBP, the lowest quintile of treated BPs was associated with the lowest total mortality in both men and women. While it should be borne in mind that these were pressures recorded between 3 and 12 months after treatment was begun, the data suggest that this time period is broadly representative of long-term BP control. In some patients, pressures in this range may be associated with an increased symptom burden, eg, from systolic orthostatic hypotension, but this appears not associated with an increase in mortality.
For DBPs, there was some suggestion of an upturn in mortality from IHD in the lowest quintile, but for total mortality there was little difference in the three lowest quintiles in either sex.
Thus, the lowest mortality occurred in the quintile with the lowest SBP. There was no increase in total mortality if the DBP was in the lowest quintile.
We conclude that efforts to achieve good BP control (by approximating BP to normal) need not be constrained by concern about the J-shaped curve. On the basis of the present data, we recommend a treated SBP <140 mm Hg and DBP <95 mm Hg. This is compatible with the conclusions of a recent review of data that concluded that a treated SBP <125 mm Hg and DBP <85 mm Hg may be optimal. 14 
